The Prediction of HER2-Targeted Treatment Response Using 64CuTetra- Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
- Author:
Inki LEE
1
;
Ilhan LIM
;
Byung Hyun BYUN
;
Byung Il KIM
;
Chang Woon CHOI
;
Kyo Chul LEE
;
Choong Mo KANG
;
Min-Ki SEONG
;
Hyun-Ah KIM
;
Woo Chul NOH
;
Sang Moo LIM
Author Information
- Publication Type:Case Report
- From:Journal of Breast Cancer 2022;25(1):69-73
- CountryRepublic of Korea
- Language:English
- Abstract: A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy. The patient underwent 64 Cu-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography/computed tomography (PET/CT) to evaluate the HER2 expression status.64 Cu-DOTA-trastuzumab accumulated in the left breast and lymph nodes but not in the lung lesions. Following trastuzumab emtansine treatment, there was a significant improvement in the lesions with 64 Cu-DOTA-trastuzumab accumulation. However, the lesions that did not accumulate 64 Cu-DOTA-trastuzumab aggravated. Therefore, it was concluded that 64 CuDOTA-trastuzumab PET/CT can be used to predict the outcome of HER2-targeted treatment by evaluating HER2 expression in breast cancer patients.
